OWC Pharmaceutical Research Corp. (OWCP) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerOWC Pharmaceutical Research Corp. (OWCP) trades at $0.00001. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for OWCP: OWCP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
OWC Pharmaceutical Research Corp. (OWCP) Healthcare & Pipeline Overview
OWC Pharmaceutical Research Corp., operating via One World Cannabis Ltd., specializes in the research and development of cannabis-based medical products. Headquartered in Ramat Gan, Israel, the company targets therapies for conditions such as multiple myeloma, psoriasis, and PTSD, while also providing consulting on international medical cannabis protocols and innovating a soluble tablet delivery system.
What Is the Investment Thesis for OWCP?
OWC Pharmaceutical Research Corp. (OWCP) presents an investment profile centered on its specialized research and development efforts in the rapidly evolving medical cannabis sector. The company's value drivers include its focused pipeline targeting conditions such as multiple myeloma, psoriasis, PTSD, chronic pain, and fibromyalgia, representing significant unmet medical needs. Its innovation in a cannabis soluble tablet delivery system could offer a differentiated product with enhanced patient compliance and bioavailability. Growth catalysts are intrinsically linked to the progression of its R&D pipeline, with successful clinical trial outcomes and subsequent regulatory approvals being critical milestones. The expanding global acceptance and legalization of medical cannabis also provide a tailwind for market penetration. Furthermore, the company's consulting services, advising on international medical cannabis protocols, offer a distinct revenue stream and leverage its specialized knowledge. However, the investment thesis is tempered by significant risks, including the high capital requirements for pharmaceutical R&D, the inherent uncertainties of clinical trials, and the complex, often restrictive, regulatory environment surrounding cannabis. Its listing on the OTC Other tier also implies lower liquidity and transparency, alongside potential challenges in securing consistent funding, as highlighted by its current market capitalization of $0.00B.
Based on FMP financials and quantitative analysis
OWCP Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap or early-stage company valuation.
- Beta: -243.53, suggesting an extremely high inverse correlation to market movements, which may indicate data anomaly or very low liquidity.
- Dividend Yield: None, as the company does not currently distribute dividends to shareholders.
- Employee Count: 9 employees, reflecting a small operational scale focused on specialized R&D.
- Primary Focus: Dedicated research and development of cannabis-based medical products and innovative delivery systems.
Who Are OWCP's Competitors?
OWCP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OWCP's Key Strengths?
Specialized focus on cannabis-based medical product research and development.
- Diverse therapeutic pipeline targeting significant conditions like multiple myeloma and PTSD.
- Innovation in drug delivery with a cannabis soluble tablet system.
- Established consulting services for medical cannabis protocols and regulatory frameworks.
What Are OWCP's Weaknesses?
Small operational scale with only 9 employees, potentially limiting R&D capacity.
- High reliance on external funding for capital-intensive pharmaceutical R&D.
- Trading on the OTC Other tier, implying higher risk, lower liquidity, and limited disclosure.
- Current market capitalization of $0.00B, indicating a very early-stage or distressed financial position.
What Are the Key Risks for OWCP?
Financial-distress signal — its Altman Z-Score of -31.25 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High capital expenditure requirements for pharmaceutical R&D without guaranteed commercial success.
- Failure to secure adequate and consistent funding to sustain long-term research and development efforts.
- Adverse regulatory changes or delays in the approval process for cannabis-based medical products.
- Intense competition from larger, better-funded pharmaceutical and biotech companies in the medical cannabis space.
- Clinical trial failures, delays, or unexpected safety concerns for its drug candidates.
What Are OWCP's Competitive Advantages?
- Specialized R&D focus on specific therapeutic applications of cannabis, building deep expertise in niche areas.
- Proprietary cannabis soluble tablet delivery system, offering a potential advantage in drug efficacy and patient convenience.
- Established consulting services leveraging specialized knowledge in international medical cannabis protocols and regulatory frameworks.
- Potential for intellectual property development around its formulations and delivery methods as its pipeline advances.
What Does OWCP Do?
OWC Pharmaceutical Research Corp., established in 2008 as Dynamic Applications Corp. before adopting its current name in December 2014, operates primarily through its subsidiary, One World Cannabis Ltd. The company is headquartered in Ramat Gan, Israel, and maintains a focused approach on the research and development of cannabis-based medical products. Its core mission revolves around exploring and formulating cannabinoid-derived therapies designed to address a diverse range of medical conditions. These target conditions include serious illnesses such as multiple myeloma, a type of blood cancer, and chronic inflammatory skin conditions like psoriasis. Additionally, OWC Pharmaceutical is actively developing treatments for neurological and pain-related disorders, specifically post-traumatic stress disorder (PTSD), chronic pain, and fibromyalgia, aiming to provide alternative or complementary therapeutic options where traditional treatments may be insufficient or have significant side effects. Beyond its therapeutic pipeline, OWC Pharmaceutical is engaged in innovative drug delivery systems. A key development in this area is its cannabis soluble tablet delivery system, which seeks to enhance the efficacy, bioavailability, and patient convenience of cannabis-based medications. This focus on novel delivery methods underscores the company's commitment to advancing the application of medical cannabis beyond conventional forms. In addition to its R&D activities, OWC Pharmaceutical extends its expertise to a consulting arm. This service provides specialized guidance to both private companies and governmental agencies, advising them on the complex landscape of international medical cannabis protocols and regulatory frameworks. This dual business model allows the company to capitalize on the burgeoning global interest in medical cannabis, not only through product development but also by facilitating its broader adoption and compliant integration into healthcare systems worldwide. With a compact team of 9 employees, OWC Pharmaceutical Research Corp. positions itself as a specialized player in the evolving medical cannabis industry, driven by scientific inquiry and a commitment to therapeutic innovation.
What Products and Services Does OWCP Offer?
- Conducts research and development of cannabis-based medical products.
- Develops therapies targeting multiple myeloma.
- Focuses on cannabis-derived treatments for psoriasis.
- Innovates solutions for post-traumatic stress disorder (PTSD) using cannabinoids.
- Researches and formulates products for chronic pain and fibromyalgia.
- Develops a proprietary cannabis soluble tablet delivery system.
- Provides consulting services on international medical cannabis protocols.
- Offers guidance on regulatory frameworks to private companies and governmental agencies.
How Does OWCP Make Money?
- Generates potential future revenue from the commercialization and sales of its developed cannabis-based medical products.
- Earns income through providing specialized consulting services to private companies regarding medical cannabis protocols.
- Secures revenue by advising governmental agencies on international medical cannabis regulatory frameworks.
- Relies on capital raises and investment to fund its ongoing research and development activities.
What Industry Does OWCP Operate In?
OWC Pharmaceutical Research Corp. operates within the "Drug Manufacturers - Specialty & Generic" industry, a segment of the broader Healthcare sector. Its specific niche is the research and development of cannabis-based medical products, positioning it within the burgeoning global medical cannabis market. This market is characterized by evolving regulatory landscapes, increasing patient acceptance, and significant scientific interest in cannabinoids' therapeutic potential. OWC Pharmaceutical competes with a diverse array of entities, ranging from large pharmaceutical companies exploring cannabinoid derivatives to numerous smaller biotech and cannabis-focused firms. The industry is marked by high R&D costs, lengthy clinical trial processes, and stringent regulatory hurdles. OWC's focus on specific conditions like multiple myeloma and PTSD, coupled with its innovative delivery system, aims to carve out a specialized position. The company also differentiates itself through its consulting services, leveraging expertise in international medical cannabis protocols, which addresses a growing need for guidance in this complex and rapidly expanding industry.
Who Are OWCP's Key Customers?
- Patients suffering from conditions such as multiple myeloma, psoriasis, PTSD, chronic pain, and fibromyalgia, who would use OWC's developed therapies.
- Healthcare providers, hospitals, and pharmacies that would prescribe and dispense the company's medical cannabis products.
- Private companies globally seeking expert guidance on navigating the complexities of medical cannabis regulations and protocols.
- Governmental bodies and agencies requiring consultation on establishing or refining their medical cannabis policies and frameworks.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
OWC Pharmaceutical Research Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -31.25 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for OWC Pharmaceutical Research Corp. stands at 237.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 8.03 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
OWC Pharmaceutical Research Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Ramat Gan, IL. The company is led by CEO Ziv Turner. OWCP has traded publicly since 2009.
Insider Activity
4 transactions · 0 purchases, 0 sales, 4 other transactions · 4 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
OWCP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
OWCP Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
· Nov 20, 2019
-
Stocks That Hit 52-Week Lows On Monday
· Aug 19, 2019
OWCP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for OWCP.
Price Targets
Wall Street price target analysis for OWCP.
OWCP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for OWCP; grades run from A+ (80-100) to F (below 30).
Leadership: Ziv Turner
Chief Executive Officer
Ziv Turner serves as the Chief Executive Officer of OWC Pharmaceutical Research Corp., where he is responsible for guiding the company's strategic direction and overseeing its operational execution. In his role, Mr. Turner leads the compact team of 9 employees, focusing on advancing the company's core mission in the research and development of cannabis-based medical products.
Track Record: Under Ziv Turner's leadership, OWC Pharmaceutical Research Corp. has maintained its dedicated focus on developing cannabis-derived therapies for conditions such as multiple myeloma, psoriasis, and PTSD. He oversees the company's efforts in innovating a cannabis soluble tablet delivery system and expanding its consulting services for international medical cannabis protocols. His management of the small team of 9 employees is central to the company's ongoing research and development initiatives.
OWCP OTC Market Information
OWC Pharmaceutical Research Corp. trades on the OTC Other tier, which is the lowest tier of the OTC Markets Group. This tier is typically for companies that do not meet the disclosure or financial standards for OTCQX or OTCQB, or that choose not to provide financial information. Companies on the OTC Other tier are not required to report to the SEC, resulting in significantly less public information and transparency compared to those listed on major exchanges like NYSE or NASDAQ. This classification generally indicates a higher risk profile for investors due to limited oversight and disclosure requirements.
- OTC Tier: OTC Other
- Limited public disclosure and financial transparency, making informed investment decisions difficult.
- High price volatility and low liquidity, leading to challenges in buying or selling shares.
- Increased susceptibility to fraud and manipulation due to less stringent regulatory oversight.
- Difficulty in accessing capital markets, potentially hindering funding for R&D and operations.
- Potential for delisting or further downgrading if disclosure requirements are not met or business operations cease.
- Verify the company's current operational status and any recent news releases directly from their website.
- Attempt to locate any available financial statements or disclosures, even if not SEC-mandated.
- Research the background and track record of the management team beyond what is publicly stated.
- Assess the viability of the company's core business model and the competitive landscape in its niche.
- Investigate any legal or regulatory actions against the company or its executives.
- Evaluate the company's funding sources and cash burn rate, if information is available.
- Understand the specific risks associated with investing in an OTC Other tier stock.
- Clearly stated business model focused on specific R&D in a growing sector (medical cannabis).
- Identified physical headquarters in Ramat Gan, Israel.
- Operates through a named subsidiary, One World Cannabis Ltd.
- Identified CEO, Ziv Turner, leading the company.
- Engagement in consulting services for governmental agencies, suggesting a level of industry recognition.
OWC Pharmaceutical Research Corp. Healthcare Stock: Key Questions Answered
How does OWC Pharmaceutical Research Corp. manage its research and development pipeline?
OWC Pharmaceutical Research Corp. manages its R&D pipeline by focusing on specific therapeutic areas where cannabis-based treatments show promise, such as multiple myeloma, psoriasis, PTSD, chronic pain, and fibromyalgia.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based solely on provided source data. Financial details are limited, particularly for a company trading on the OTC Other tier, which typically has less stringent disclosure requirements.